Weight-loss figures travel badly. A number from a trial gets detached from the dose it refers to, the length of time it took, the people it was measured in and the placebo group it should be compared against, and by the time it reaches a headline it has usually grown. It is worth setting out what the orforglipron trials actually found, because the real figures are good and the inflated versions circulating are not helpful to anyone deciding whether to take it.
ATTAIN-1: the main obesity trial
ATTAIN-1 studied adults with obesity, or overweight with a weight-related condition, who did not have type 2 diabetes. Participants on the highest dose lost an average of around 11% of their starting body weight over 72 weeks. The placebo group, who received the same dietary and activity support without the active medicine, lost around 2%. That comparison is the part most often dropped, and it is the part that establishes the medicine is doing something: the difference between the groups, roughly nine percentage points, is the effect attributable to the drug rather than to everything else the trial provided.
The figures behind the average
Averages conceal distribution, so the supporting numbers are more informative. Just over half of participants on treatment lost at least 10% of their body weight, compared with around one in eight on placebo. Average waist circumference fell by roughly 10 cm against about 3 cm on placebo, which matters because waist measurement tracks visceral fat, the fat around the organs that carries most of the metabolic risk. Someone whose waist has reduced by 10 cm has made a change to their health that the scales alone understate.
ATTAIN-2: alongside type 2 diabetes
ATTAIN-2 studied adults with obesity or overweight who also had type 2 diabetes, and found average weight loss of around 10.5% over the same 72 weeks. That it is slightly lower than ATTAIN-1 is expected rather than disappointing: weight loss is consistently harder to achieve alongside type 2 diabetes, and the same pattern appears across every medicine in this class. Read properly, near-parity between the two populations is a reasonably strong result.
How this compares with the alternatives
Honestly, and this is where the coverage has been least useful: orforglipron produced the most modest average of the current GLP-1 options. Tirzepatide, in Mounjaro, produced around 21% at its highest dose over 72 weeks. Semaglutide, whether as the Wegovy injection or the Wegovy pill, produced around 15% over 68 weeks. These come from separate trials with different participants and designs, so the exact gaps should not be over-read, but the ordering has been consistent enough that it is not seriously disputed. What orforglipron offers is not the largest weight loss. It is the least demanding way of taking a GLP-1 medicine.
Why 10% is the number that matters clinically
It is tempting to judge these results against the largest figure available, but the clinically meaningful thresholds are lower than people expect. Losing 5% of body weight measurably improves blood pressure, blood sugar and cholesterol. At 10% those gains deepen and joint pain and sleep apnoea typically improve. Beyond that, benefits continue to accumulate but each further kilogram matters slightly less to health, even if it matters a great deal to how someone feels. A treatment that puts the average person past 10%, and gets more than half of them there, is doing the job that weight-management medicine exists to do.
Where the inflated figures come from
It is worth naming this, because misleading numbers are circulating. Some pages promoting orforglipron display figures well above what the trials reported, occasionally in the region of 20%, while carrying the correct figure of around 11% in their own body text further down the page. Where a larger number appears, it usually belongs to a different medicine, most often tirzepatide, or has been lifted from a subgroup that lost the most rather than from the trial average. If you encounter a weight-loss claim for orforglipron substantially above 11%, the right response is to check which trial, which dose, which population and over what period, and in most cases at least one of those will not match.
What the trials could not tell us
Seventy-two weeks is a substantial trial and a short period in the life of a long-term treatment. The results describe what happens through dose escalation and into a settled dose over roughly a year and a half. They do not describe five years. They also come from trial conditions, where participants receive structured support and are monitored closely, and real-world results are typically somewhat lower than trial results across every weight-management medicine, largely because adherence in ordinary life is worse than adherence in a study. That is not a criticism of the evidence; it is how to read it.
What actually predicts your result
Trial averages are a starting point rather than a forecast. What consistently separates people who do well from people who do not is whether they reach and stay on an effective dose, whether protein intake and some resistance exercise protect muscle so that the weight lost is predominantly fat, whether the dietary changes are sustainable rather than punitive, and whether treatment continues long enough for the result to consolidate. The medicine reduces appetite, which makes all of that easier. It does not do any of it for you, and the difference between an 11% average and a much better personal outcome usually lies there.
